Xeris Biopharma Holdings, Inc. (XERS): Total Liabilities
$369.84M
As of 2025-12-31
$421.64M
As of 2026-06-30
+7.3%
3-year compound annual growth
+24.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $369.84M | +4.9% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $352.68M | +7.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $329.38M | +10.0% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $299.33M | +43.1% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $209.13M | +66.8% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $125.39M | n/a | 2022-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $420.83M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
Compare XERS, EOLS, CRMD, HROW side by side · Screen every company in Pharmaceutical Preparations ↗